IGF-1 DES: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 50 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Administration Timing | In vitro studies demonstrate IGF-1 DES is approximately 10-fold more potent than native IGF-1 for cell proliferation. No in vivo human timing studies exist. | Community emphasizes peri-workout timing (10-15 minutes before or immediately after training) to capitalize on the very short half-life and target activated muscle tissue. DES is specifically chosen over LR3 for its rapid, localized action. | moderate The peri-workout timing strategy is community-derived and based on the pharmacokinetic profile (very short half-life) rather than clinical data. |
| Site-Specific Growth | No published human studies have demonstrated site-specific muscle growth from localized IGF-1 DES injection. The concept is based on in vitro potency data and the peptide's short half-life. | Site-specific injection into trained muscles is the primary community use case for IGF-1 DES. The short half-life (~20-30 minutes) is believed to enable localized effects before systemic clearance. | high IGF-1 DES is specifically chosen over LR3 in the community for localized effects. The short half-life theoretically supports more localized action, but this has not been validated in human studies. |
| Dose Range | No human dosing studies exist. In vitro studies use nanogram concentrations. Community doses are extrapolated from anecdotal experience. | Community uses 20-100 mcg daily, with maximum recommended dose of 100 mcg. All dosing is community-derived without clinical validation. | high Without human pharmacokinetic data, appropriate dosing remains uncertain. Community consensus on dose limits is based on side effect observation (primarily hypoglycemia). |
Compare these community approaches with published research findings.
Community Protocols
Pre-Workout Site Injection Protocol
Popular- Route
- Intramuscular (site-specific)
- Dose
- 50-100 mcg total, split across 2-4 muscle groups
- Frequency
- Training days only
- Duration
- 4-6 weeks
Injected 10-15 minutes pre-workout into muscles to be trained. Split dose across target muscle groups.
Post-Workout Protocol
Common- Route
- Intramuscular or Subcutaneous
- Dose
- 50-100 mcg
- Frequency
- Immediately post-workout
- Duration
- 4-6 weeks
Injected within 15 minutes after training; combined with post-workout nutrition to manage blood sugar
Conservative Protocol
Common- Route
- Subcutaneous
- Dose
- 20-50 mcg
- Frequency
- Once daily on training days
- Duration
- 4 weeks
Lower-dose SubQ approach for beginners; reduced hypoglycemia risk compared to higher IM doses
Lagging Body Part Protocol
Niche- Route
- Intramuscular (site-specific)
- Dose
- 25-50 mcg per muscle group
- Frequency
- Training days for target muscles
- Duration
- 4-6 weeks
Focused injection into underdeveloped muscle groups; based on site-specific growth theory
Stacking Patterns
IGF-1 DES + IGF-1 LR3 Alternating Protocol
CommonAlternating short-acting localized (DES) and long-acting systemic (LR3) IGF-1 analogs for comprehensive growth factor stimulation
IGF-1 DES + HGH
CommonHGH for systemic GH/IGF-1 elevation with DES for targeted peri-workout IGF-1 receptor activation in trained muscles
IGF-1 DES + MGF
NicheCombined growth factor approach targeting different phases of muscle repair; MGF for satellite cell activation and DES for proliferation
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 50+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|IGF-1 DES experience reports and site injection discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|IGF-1 DES vs LR3 comparison threads(accessed 2026-02-16)
- Swolverine|IGF-1 DES Guide (benefits, dosage, stacking, safety)(accessed 2026-02-16)
- Peptides.org|IGF-1 DES Dosage Calculator and Chart(accessed 2026-02-16)
- Muscle and Brawn|IGF-1 Peptide Guide (benefits, uses, dosage)(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for IGF-1 DES (Des(1-3) IGF-1). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
IGF-1 DES is used in the bodybuilding community as a short-acting, high-potency growth factor for localized muscle growth. Its very short half-life (~20-30 minutes) differentiates it from IGF-1 LR3 and positions it as the preferred IGF-1 variant for site-specific injection protocols.
Understanding Protocol Divergence#
Localized Growth Theory#
The primary community use case for IGF-1 DES is site-specific muscle injection, based on the theory that its short half-life enables localized action before systemic clearance. While this has pharmacokinetic logic (shorter half-life = less systemic distribution), no published human studies have validated site-specific muscle growth from localized IGF-1 injection.
No Human Clinical Data#
Like IGF-1 LR3, IGF-1 DES has no human clinical trial data. All dosing and administration protocols are community-derived. The compound's primary research application is as a cell culture reagent, and community use represents a departure from its intended purpose.
Commonly Reported Outcomes#
- Muscle pumps: Enhanced muscle fullness during training when injected pre-workout
- Localized growth: Some users report improved development of injected muscle groups (subjective)
- Hypoglycemia: Blood sugar drops, especially at higher doses or without food
- Short-lived effects: Effects are perceived as brief due to the short half-life
- Pain at injection site: Some users report injection site discomfort with IM administration
Important Caveats#
- No human clinical data exists
- Hypoglycemia is a significant safety concern
- Site-specific growth is unproven in human studies
- Product quality varies significantly
- Very short half-life means rapid clearance but also brief activity window
Reconstitution and Storage Practices#
- Reconstitution: 0.6% acetic acid or bacteriostatic water per vial
- Storage: Refrigerated at 2-8 degrees C; very temperature sensitive
- Shelf life: Use within 1-2 weeks of reconstitution (less stable than LR3)
- Note: IGF-1 DES is fragile; avoid shaking and keep refrigerated at all times
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About IGF-1 DES
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.